Durvalumab in Stage III Non-Small-Cell Lung Cancer

N Engl J Med. 2018 Mar 1;378(9):869-870. doi: 10.1056/NEJMc1716426.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • Carcinoma, Non-Small-Cell Lung*
  • Combined Modality Therapy
  • Humans
  • Lung Neoplasms*
  • Neoplasm Staging

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • durvalumab